Richard Scheller

Dr. Richard Sheller is an industry veteran with decades of oncology drug development and leadership experience. Dr. Scheller currently serves as a member of the Board of Directors and Chairman of Research & Development at BridgeBio. He is also a member of the Board of Directors of 23andMe, Alector, Inc., DICE Therapeutics, and Maze Therapeutics. Dr. Scheller has previously served as the Chief Science Officer and Head of Therapeutics at 23andMe. From 2001 to 2014, Dr. Scheller was the Senior Vice President of Research and then Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc. From 2009 to 2014, he was a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd. Dr. Scheller is a recipient of the Kavli Prize in Neuroscience and the Albert Lasker Basic Medical Research Award. He is a Fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Sciences and the National Academy of Medicine. Dr. Scheller holds a BSc in Biochemistry from the University of Wisconsin-Madison and a PhD in Chemistry from the California Institute of Technology.